A committee for the European Union’s pharmaceutical regulatory agency backed changes to the dosing schedule for Bristol-Myers Squibb‘s (NYSE:BMY) Opdivo cancer drug, the company touted today.
The Committee for Medicinal Products for Human Use recommended that the European Commission approve a dosing schedule of 480-mg infused over 60 minutes every four weeks as an option for patients with advanced melanoma and previously-treated renal cell carcinoma. The committee also backed a shorter dosing option of 240-mg infused over 30 minutes every two weeks for Opdivo’s six approved monotherapy indications in the EU.
Get the full story at our sister site, Drug Delivery Business News.